<< Palomar SlimLipo body sculpting laser to be featured on The Dr. Oz Show | New chemotherapy agents improve survival time for patients with metastatic colorectal cancer >>

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | Nederlands | Русский | Polski

Human Genome Sciences announces Phase 2 results of mapatumumab combination therapy for NSCLC

Published on March 17, 2010 at 7:43 AM · No Comments

Human Genome Sciences, Inc. (Nasdaq: HGSI) today announced the results of its randomized Phase 2 trial of mapatumumab (HGS-ETR1) in combination with the chemotherapy agents paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC).

The results showed no difference in disease response or progression-free survival for the combination that included mapatumumab vs. the control group, and showed that mapatumumab was well tolerated in this study. HGS expects to present the results in full at an appropriate scientific meeting later in 2010.

Source Human Genome Sciences

7faf231b-9d16-41dd-9674-169270402661|0|.0

Posted in: Drug Trial News | Medical Procedure News | Medical Condition News

Tags: Anthrax, Antibody, Apoptosis, Cancer, Carboplatin, Cell, Chemotherapy, Coronary Heart Disease, Diabetes, Hepatitis C, Lung Cancer, Lupus, Monoclonal Antibody, Multiple Myeloma, Non-Small Cell Lung Cancer, Oncology, Paclitaxel, Small Cell Lung Cancer, Type 2 Diabetes

Related posts

Cholesterol receptor allows entry of HCV virus into human liver cellsA molecule embedded in the membrane of human liver cells that aids in cholesterol absorption also al...
EMA accepts Pfizer's regulatory submissions of two investigational cancer drugs for reviewPfizer Inc. announced today that the European Medicines Agency (EMA) has accepted Pfizer's regulator...
Ipsen, Active Biotech sign deal to co-develop and commercialize TASQActive Biotech AB and Ipsen announced today that they have entered into a broad partnership to co-de...
No safe level of exposure to secondhand smokeThe following is a statement by Cheryl G. Healton, DrPH, President and CEO of Legacy on the U.S. Sur...
New findings shed light on biology of neuropsychiatric diseasesThe biggest surprise to me was that we could rescue the autistic phenotype [in the human cells] to s...
GI Dynamics' EndoBarrier therapy to treat type 2 diabetes and obesity granted European CE mark approvalGI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today ...
Access Pharmaceuticals reports significant progress in Cobalamin-targeted drug-delivery program for siRNA therapiesACCESS PHARMACEUTICALS, INC., a biopharmaceutical company leveraging its proprietary drug-delivery p...
Omeros net loss for second-quarter 2010 increases to $7.8 millionOmeros Corporation, a biopharmaceutical company committed to discovering, developing and commerciali...
Intellect Neurosciences receives USPTO Notice of Allowance for IN-N01 monoclonal antibody patentIntellect Neurosciences, Inc. announced today that it has received a Notice of Allowance from the Un...
Pfizer discontinues ADVIGO 1018 trial of figitumumab-erlotinib combination therapy for advanced NSCLCPfizer Inc. announced today the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 t...
Abbott enters into agreement with GSK to develop molecular diagnostic test for skin cancer treatmentAbbott announced today that it has entered into an agreement with GlaxoSmithKline (GSK) to develop a...
Key data, information and analysis on global diabetes care devices marketResearch and Markets (http://www.researchandmarkets.com/research/ba78e4/the_future_of_the) has annou...
'Make Today the Day' public awareness campaign to quit smoking launchedAt a time when many smokers consider quitting for the New Year, today is a timely launch of a partne...
Interim data from Geron's ongoing imetelstat trial presented at the AACR-NCI-EORTC conferenceGeron Corporation today announced the presentation of interim data from its ongoing trial of imetels...
FDA approves clinical studies of novel anti-cancer drug developed by Italian researchersNerviano Medical Sciences (NMS) has secured Food and Drug Administration (FDA) approval to conduct f...
Suicide death of anthrax scientist puts pressure on the FBI to come cleanThe Federal Bureau of Investigation (FBI) in the United States is coming under increasing pressure t...
DNA vaccines boosted by dendritic cellsThe concept sounds ideal: vaccines made of DNA that could be taken in by other cells and give instru...
Study finds flaws in cancer trialsCancer research and drug development are yielding more sophisticated candidate therapies, but invest...
Bevacizumab plus chemo extends survival beyond one year for large group of advanced lung cancer patientsPatients with a particular type of advanced lung cancer may have a new option based on data presente...

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.

Quirky Comment Title
Name*
E-mail*
Country Country flag

b i u quote

Comment
Preview

Leave this field blank

News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.